Comprehensive notes: REMIX trials of remibrutinib for chronic spontaneous urticaria ( CSU )

Housekeeping and training context

• Presenter: Jessica Hopp, Associate Director of Product Training for remibrutinib

• Focus: REMICS clinical trial training in anticipation of potential approval; active participation and note-taking encouraged

• Q&A: Jonathan (medical expert) will present; questions can be submitted in chat and answered at the end

• Disclaimer: remibrutinib is investigational; efficacy/safety data in REMICS I & II published in the New England Journal of Medicine and may differ from final label; no guarantee of commercial availability for uses under investigation; content for internal use only; share approved material with customers

REMICS clinical trial overview

• Goal: understand the goal, study design, and safety/results of REMICS I and REMICS II evaluating remibrutinib for CSU

• Learning objectives

  • Explain goal and study design of REMICS I & II

  • Describe efficacy results of REMICS I & II

  • Summarize safety results of REMICS I & II

• Study design highlights

  • Two identical phase III trials conducted in parallel for scientific rigor and reproducibility

  • Global, multicenter, double-blind, randomized, placebo-controlled

  • Dose: remibrutinib 25 mg twice daily (BID), add-on to background second-generation H1 antihistamines

  • Population: CSU patients inadequately controlled on background H1 antihistamines

  • Duration: 52 weeks total; 24-week double-blind period followed by open-label remibrutinib; extension study option after week 52

  • Randomization ratio: 2:1 (remibrutinib:placebo)

  • Key eligibility: ≥18 years old; CSU for ≥6 months; inadequate control on ≥1 daily second-generation H1 antihistamine with documented hives

  • Background therapy allowed: up to 4 H1 antihistamine doses per day; prescription of concomitant antihistamines allowed per guidelines

CSU background and mechanism of action for BTK inhibitors

• CSU definition: chronic spontaneous urticaria with urticaria and/or angioedema lasting >6 weeks

• BTK role in CSU pathogenesis

  • Mast cell activation starts with FcεRI (high-affinity IgE receptor) engagement by IgE or IgG (autoantibodies)

  • Receptor cross-linking triggers downstream signaling; BTK is a key signaling molecule in this cascade

  • Signaling leads to mast cell degranulation, releasing histamine and other mediators causing hives and angioedema

• Remibrutinib mechanism

  • Oral small-molecule BTK inhibitor; targets BTK signaling to prevent mast cell degranulation

  • Result: reduced release of histamine and inflammatory mediators, improving CSU symptoms

• Clinical context

  • REMICS I & II evaluated efficacy/safety of remibrutinib on CSU patients already treated with second-generation H1 antihistamines

  • Phase III data published in NEJM used to support discussion of remibrutinib’s potential role

Study population and baseline characteristics

• Demographics

  • Age: predominantly 30s–50s (adult CSU population)

  • Gender: REMICS I showed ~68.3% male, 31.7% female; REMICS II showed ~65.3% male, 34.7% female (demographics align with CSU patterns, though CSU often female-predominant in broader data)

• Disease characteristics

  • Disease duration: mean duration >5 years (typical for moderate–severe CSU)

  • Disease severity at baseline: about 60% had severe CSU (US >28 on UA7 scale), though inclusion allowed moderate to severe

  • Prior anti-IgE exposure: ~31% in REMICS I and REMICS II; washout minimum of 6 months before randomization

• Inclusion/exclusion fragments

  • Included: adults with CSU uncontrolled on background antihistamines; documented hives

  • Excluded: clearly inducible urticarias (SINDU predominant), history of malignancy, pregnancy/lactation or planning pregnancy, significant comorbidities, on anticoagulants, or on dual antiplatelet therapy

  • Baseline meds: allowed limited antihistamine dosing; dual antiplatelet/anticoagulant exclusion to minimize bleeding risk

Efficacy endpoints and results (remibrutinib vs placebo)

• Primary endpoints (scenario one and scenario two)

  • Scenario one: change from baseline in UA7 (Urticaria Activity Score over 7 days) at week 12

  • Scenario two: changes in itch severity score and hive severity score at week 12 (co-primary)

• UA7 definition and scoring

  • UA7 combines two PRO components collected twice daily: itch severity and hive severity

  • Itch severity score (I_d) per 12h block: 0 = none, 1 = mild, 2 = moderate, 3 = severe; measured twice daily

  • Hive severity score (H_d) per 12h block: 0 = none, 1 = 1–6 hives, 2 = 7–12 hives, 3 = >12 hives; measured twice daily

  • Weekly UA7 calculation (7 days):

  • $UA7 = rac{1}{?} ext{(definition clarified in trial). The practical approach used in results: } UA7 = \bigg( ext{sum of I<em>d + H</em>d over 7 days}\bigg)$

  • Range: 0 to 42; 0 = symptom-free; 1–6 = minimal; 7–15 = mild; 16–27 = moderate; 28+ = severe

• Key efficacy findings (week 12, double-blind period)

  • Change from baseline in UA7: remibrutinib produced greater reduction than placebo in both REMICS I and II; mean decreases around -20 points with remibrutinib vs around -12 points with placebo

  • Change in itch severity score and hive severity score (week 12): remibrutinib produced roughly 9–10 point reductions on both components vs placebo reductions of around 6–7

• Secondary efficacy endpoints

  • Proportion achieving well-controlled CSU (UA7 < 6) at week 2 and week 12

  • Week 2: ~30–33% on remibrutinib vs ~3–6% on placebo

  • Week 12: ~46–50% on remibrutinib vs ~19–25% on placebo

  • Proportion achieving complete control (UA7 = 0) at week 12

  • Remibrutinib: ~27.9–31.1%

  • Placebo: ~6.5–10.5%

• Overall interpretation

  • All primary and key secondary endpoints favored remibrutinib over placebo in both REMICS I and REMICS II

  • Efficacy observed early (as early as week 2) and sustained through week 12; sustained further through later weeks based on extension data (details forthcoming)

Safety and tolerability

• Overall safety profile

  • Common adverse events (≥3% in remibrutinib vs placebo): nasopharyngitis, upper respiratory tract infections, headaches, COVID-19 infection, urticaria, urinary tract infections

  • Petechiae: imbalancedly higher in remibrutinib (3.8%) vs placebo (0.3%); led to discontinuation in 1 remibrutinib patient; no major bleeding events reported

  • Serious adverse events: balanced between arms (~3% each)

  • Adverse events leading to discontinuation: rare and similar between arms (2.8% remibrutinib vs 2.9% placebo); most discontinuations due to physician/patient preference rather than AEs

• Laboratory and vital signs

  • Infections: similar rates between arms (~33–34%) with no opportunistic infections

  • Liver enzymes (ALT/AST): small numbers; elevations occurred at similar rates between arms; no consistent pattern of clinically significant hepatotoxicity

  • Blood counts and coagulation markers: no meaningful reductions or abnormalities; platelets remained stable; no clinically meaningful bleeding risk signal beyond petechiae

  • Vital signs: small fluctuations in blood pressure; overall balanced between arms; no hypertension signal attributable to treatment

• Petechiae mechanistic discussion

  • Petechiae are small, non-blanching skin/mucosal spots due to bleeding in the dermis

  • In REMICS, petechiae were mostly mild/moderate and did not typically require intervention; distribution varied but often on arms/legs

  • BTK inhibition can affect platelet signaling (BTK participates in platelet aggregation), but redundancy in platelet pathways preserved overall hemostasis; no major bleeding events observed

• Immunity and infection risk

  • No evidence of global immunosuppression: immunoglobulin levels remained normal; B-cell counts not decreased; infections did not increase overall; responses remained adequate against common infections during the COVID-19 era

• Rebound, extension, and long-term considerations

  • Rebound itching after discontinuation discussed for phase II extension (not fully public for phase III extension); results suggest possible return of symptoms after stopping therapy

  • Long-term extension data expected to be published later (potentially 2026–2027)

Pharmacology and pharmacokinetics ( PK/PD ) notes

• Half-life and dosing rationale

  • Remibrutinib half-life: ≈ 2 hours; supports BID dosing to maintain 24-hour coverage

  • Full drug exposure considerations: despite short half-life, BID dosing maintains efficacy across a 24-hour period; observed sustained efficacy through week 52 in trial data

• Selectivity and safety rationale

  • Remibrutinib is designed as a selective BTK inhibitor with high specificity for BTK; reduced off-target effects compared to earlier BTK inhibitors used in oncology

  • JAK-STAT concerns: Remibrutinib does not inhibit JAK pathways; binding data show negligible JAK-3 interaction; not a JAK inhibitor despite name similarity in some discussions

• Comparison to small molecules vs biologics

  • Remibrutinib = small molecule BTK inhibitor; differentiates from biologics (e.g., monoclonal antibodies) in mechanism, manufacturing, and PK/PD properties

FAQ highlights and practical takeaways

• Two identical trials rationale

  • Ensures data reproducibility and robust regulatory evidence; FDA and regulators often require two independent confirmatory trials

• Immunology questions (CSU endotypes)

  • CSU endotypes discussed: type 1 (autoallergic, IgE-mediated) and type 2B (autoimmune, IgG-mediated) in the mast cell pathway; understanding endotypes helps frame the disease mechanism and potential responders

• Petechiae management and clinical interpretation

  • Petechiae observed in a minority; generally mild and non-disruptive; monitor for bleeding signs; no need for routine cessation unless clinically warranted

• Antihistamine background therapy in trials vs real-world use

  • All patients continued background antihistamines per guidelines, with optional up-titration up to 4x daily; remibrutinib efficacy observed across varying antihistamine regimens

• Pregnancy and malignancy considerations

  • Pregnancy excluded from trials; labeling will address this; previous malignancy exclusion applied to trial participants; real-world use will require careful consideration per label

• Extension studies and future data

  • Extension study results and analyses (e.g., anti-IgE-exposed subgroups, long-term safety, and durability) anticipated in subsequent publications; current data support sustained efficacy through 52 weeks in trial participants

Practical implications for clinicians and stakeholders

• Positioning remibrutinib in CSU care

  • Remibrutinib adds a targetable BTK mechanism to treat CSU patients with inadequate control on second-generation H1 antihistamines

  • Usage as add-on therapy aligns with guideline frameworks emphasizing combination therapy readiness

• Safety monitoring priorities

  • Monitor for petechiae, infections, liver enzymes, and hematologic parameters as part of standard safety monitoring in trials; no major bleeding signals observed in REMICS I & II

• Patient counseling considerations

  • Early onset of symptom improvement observed (as early as week 2) with sustained benefits; discuss potential for rebound itching after discontinuation and the need for gradual management if stopping therapy

  • Explain differential from JAK inhibitors and biologics; emphasize selectivity and safety profile as described in trials

Key numerical references and formulas (LaTeX)

• Urticaria Activity Score over 7 days (UA7) composition

  • $UA7 = \bigg( ext{sum of }(I<em>d + H</em>d) ext{ over }d = 1 ext{ to } 7\bigg)$

  • Where each daily itch severity Id ∈ {0,1,2,3} and hive severity Hd ∈ {0,1,2,3}

  • UA7 range: 0 to 42

• UA7 severity categories

  • 0: symptom-free; 1–6: minimal CSU; 7–15: mild CSU; 16–27: moderate CSU; 28–42: severe CSU

• Randomization and dosing

  • Randomization: 2:1 (remibrutinib:placebo)

  • Dose: $ext{Remibrutinib} = 25 ext{ mg} imes ext{BID}$

• Study duration and design

  • Total study duration: 52 weeks

  • Double-blind phase: weeks 0–24; open-label remibrutinib for weeks 24–52

• Pharmacokinetics

  • Half-life: $t_{1/2} \approx 2 ext{ hours}$

  • BID dosing used to ensure 24-hour coverage

• Key efficacy outcomes (week 12)

  • Change from baseline in UA7: approximately −20 points with remibrutinib vs around −12 points with placebo

  • Change in itch severity and hive severity scores: ~−9 to −10 with remibrutinib vs ~−6 to −7 with placebo

• Secondary endpoint proportions (week 2 and week 12)

  • Well-controlled CSU (UA7 < 6): week 2 ≈ 30–33% (remibrutinib) vs ≈ 3–6% (placebo); week 12 ≈ 46–50% (remibrutinib) vs ≈ 19–25% (placebo)

  • Complete control (UA7 = 0): week 12 ≈ 27.9–31.1% (remibrutinib) vs ≈ 6.5–10.5% (placebo)

• Safety signals (selected)

  • Petechiae: ≈ 3.8% (remibrutinib) vs ≈ 0.3% (placebo)

  • Serious adverse events: ≈ 3% in both arms

  • Any adverse event: balanced between arms; no major bleeding events reported

  • Infections (overall): ≈ 33–34% in both arms; serious infections rare (~0.7%)

Notes on reporting and sharing

• Content includes detailed trial data discussed in a training context

• Some Q&A content reflects internal responses and may reference data not yet published in the label or public domain

• Information intended for medical/educational purposes; should not be directly shared with customers beyond approved label and materials